Executive Vice President, Chief Financial Officer and Head of Business Development · Seres Therapeutics, Inc. (MCRB)

David Arkowitz

A named executive officer of Seres Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,786,650

Salary $470,900Stock awards $0

FY2021: $5,226,695

2nd of 5 named executive officers at Seres Therapeutics by FY2022 total.

5 named officers on file for Seres Therapeutics, FY2022

David Arkowitz’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • MCRB’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Seres Therapeutics’s whole pay program stands against its peers

  • Seres Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MCRB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2023 (DEF 14A).

Free

Get David Arkowitz’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

David Arkowitz compensation by year

Seres Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Seres Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$265,417$470,900
Bonus$50,000$0
Stock awards$916,100$0
Option awards$3,896,775$1,116,630
Non-equity incentive$93,994$190,000
Pension and deferred compensation$0$0
All other$4,409$9,120
Total$5,226,695$1,786,650

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Seres Therapeutics, Inc. DEF 14A filed April 25, 2023, accession 0000950170-23-014419, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Seres Therapeutics, Inc. filed document, accession 0000950170-23-014419. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2023.

$5.2M
$1.8M
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU42,500$238,000—
Option168,750—$20.19
Option190,000—$7.38

Per the Outstanding Equity Awards at Fiscal Year-End table in Seres Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Seres Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Eric ShaffPresident and Chief Executive Officer$4,006,248
David Arkowitz · this pageExecutive Vice President, Chief Financial Officer and Head of Business Development$1,786,650
Lisa MoltkeExecutive Vice President and Chief Medical Officer$1,734,614
Matthew HennExecutive Vice President and Chief Scientific Officer$1,672,303
Paula CloghessyExecutive Vice President and Chief People Officer$1,632,966

The full Seres Therapeutics compensation record

free company brief

This page is one person within Seres Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Seres Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Arkowitz's compensation dossier · One-time report. No refunds.